New Data from Studies, Enrollment in Registry, Upcoming Conferences, and Stock Price Movement - Analyst Notes on Alexion, Boston Scientific, Thermo Fisher Scientific, Valeant, and Jazz Pharmaceuticals

NEW YORK, April 22, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Boston Scientific Corporation (NYSE:BSX), Thermo Fisher Scientific Inc. (NYSE:TMO), Valeant Pharmaceuticals Intl Inc (NYSE:VRX), and Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1204-100free

--

Alexion Pharmaceuticals, Inc. Analyst Notes 

On April 11, 2014, Alexion Pharmaceuticals, Inc. (Alexion) announced that it will present new data from the extension phase of two clinical studies, examining the long-term efficacy and safety of asfotase alfa in infants and juveniles with hypophosphatasia (HPP) - an inherited, ultra-rare metabolic disorder. Alexion stated that it will present the said data along with presentation of results from a retrospective natural history study of patients with perinatal and infantile HPP at the joint meeting of the Pediatric Academic Societies (PAS) and the Asian Society for Pediatric Research which is scheduled on May 3 to May 6, 2014 in Vancouver, B.C., Canada. Alexion also stated that several abstracts summarizing the asfotase alfa studies and the HPP natural history study will also be presented via poster session during the meeting. The full analyst notes on Alexion Pharmaceuticals, Inc. are available to download free of charge at:

http://www.analystsreview.com/1204-ALXN-22Apr2014.pdf

--

Boston Scientific Corporation Analyst Notes 

On April 10, 2014, Boston Scientific Corporation (Boston Scientific) reported that it has enrolled its first patient in a new registry to evaluate clinical outcomes and the economic value of the Vercise™ Deep Brain Stimulation (DBS) System in patients with Parkinson's disease (PD). According to the Company, the Vercise DBS System is an implantable medical device which will enable customized therapy, helping to improve the quality of life for PD patients. Prof. Dr. Vesper, Department of Functional Neurosurgery and Stereotaxy at Heinrich-Heine University Hospital in Dusseldorf, Germany, remarked, "The unique features of the Vercise System, including the ability to selectively stimulate targeted areas of the brain via multiple independent current control, as well as the longevity of the Zero Volt™ battery, are designed for improved patient outcomes and enhanced clinical effectiveness." Boston Scientific expects to enroll up to 300 patients in the study with PD. The full analyst notes on Boston Scientific Corporation are available to download free of charge at:

http://www.analystsreview.com/1204-BSX-22Apr2014.pdf

--

Thermo Fisher Scientific Inc. Analyst Notes 

Thermo Fisher Scientific Inc. posted on its events page that it will hold its Q1 2014 earning conference call on Wednesday, April 23, 2014, at 8:30 a.m. ET. The live webcast of the call will be made available at the Company's website. The full analyst notes on Thermo Fisher Scientific Inc. are available to download free of charge at:

http://www.analystsreview.com/1204-TMO-22Apr2014.pdf

--

Valeant Pharmaceuticals Intl Inc Analyst Notes 

On April 11, 2014, shares in Valeant Pharmaceuticals Intl Inc. (Valeant) dropped 3.68% to end trading at $118.79. Over the past six-month trading period, Valeant's shares gained 8.55%, in line with the Dow Jones Industrial Average which increased by 5.18% during the same trading period. The full analyst notes on Valeant Pharmaceuticals Intl Inc are available to download free of charge at:

http://www.analystsreview.com/1204-VRX-22Apr2014.pdf

--

Jazz Pharmaceuticals plc Analyst Notes 

On April 11, 2014, Jazz Pharmaceuticals plc's (Jazz Pharmaceuticals) stock price slipped by 0.77% to close trading at $128.61 per share. Over the five-day trading period, Jazz Pharmaceuticals' stock fared better with a 1.43% increase, compared with the Nasdaq Composite which dropped 3.10% during that same period. The full analyst notes on Jazz Pharmaceuticals plc are available to download free of charge at:

http://www.analystsreview.com/1204-JAZZ-22Apr2014.pdf

--

About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

--

=============

EDITOR NOTES: 

• This is not company news. We are an independent source and our views do not reflect the companies mentioned.
• Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
• This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
• If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
• For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
• Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE 

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE 

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED 

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED